Fu Zhiwen, Zhou Jiafeng, Pan Hongye, Yang Song, Pan Zhenzhen, Shen Yujia, Yao Jianbiao, Hu Jiangning
School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Jiangxi Conba Traditional Chinese Medicine Co.,Ltd, Shangrao, China.
Front Pharmacol. 2025 Mar 26;16:1575280. doi: 10.3389/fphar.2025.1575280. eCollection 2025.
The QingGan LiDan capsule (QGLD) consists of five traditional Chinese herbs, which have been used for hepatobiliary diseases such as jaundice. However, the effects and mechanisms by which QGLD prevent alcoholic liver diseases (ALD) remain unknown.
Investigate the therapeutic potential of QingGan Lidan capsule (QGLD) in alleviating alcohol-induced liver injury.
Acute alcoholic liver injury model and chronic and Binge ethanol Feeding Model (NIAAA) model were established. Mice were administered QGLD (360, 720, 1,440 mg/kg) or vehicle. Liver function indicators (ALT, AST), serum lipid (TC, TG), antioxidant markers (SOD, GSH, MDA), lipid metabolism/transport genes relative expression levels, liver and ileal villus morphology were analyzed. Network pharmacology analysis was also performed to identify potential targets and pathways of QGLD.
QGLD reduced serum ALT, AST, hepatic TC, TG, and lipid droplet accumulation in both models. It upregulated antioxidant enzymes (SOD, GSH) and downregulated MDA. QGLD regulated the mRNA levels of genes related to the NRF2/KEAP1 pathway and lipid transport. Network pharmacology identified 221 potential targets.
QGLD mitigates alcohol-induced liver injury by reducing lipid accumulation, regulating lipid transport and enhancing antioxidant capacity. This supports its potential application in ALD management.
清肝利胆胶囊(QGLD)由五种传统中药组成,已用于治疗黄疸等肝胆疾病。然而,QGLD预防酒精性肝病(ALD)的作用及其机制尚不清楚。
研究清肝利胆胶囊(QGLD)在减轻酒精性肝损伤方面的治疗潜力。
建立急性酒精性肝损伤模型以及慢性和暴饮乙醇喂养模型(NIAAA)。给小鼠灌胃QGLD(360、720、1440mg/kg)或赋形剂。分析肝功能指标(ALT、AST)、血脂(TC、TG)、抗氧化指标(SOD、GSH、MDA)、脂质代谢/转运基因的相对表达水平、肝脏和回肠绒毛形态。还进行了网络药理学分析以确定QGLD的潜在靶点和途径。
在两种模型中,QGLD均降低了血清ALT、AST、肝脏TC、TG以及脂质滴积累。它上调了抗氧化酶(SOD、GSH)并下调了MDA。QGLD调节了与NRF2/KEAP1途径和脂质转运相关基因的mRNA水平。网络药理学确定了221个潜在靶点。
QGLD通过减少脂质积累、调节脂质转运和增强抗氧化能力来减轻酒精性肝损伤。这支持了其在ALD管理中的潜在应用。